3-Rhamnosyl-Glucosyl Quercetin, Quercetin 3 Rutinoside, Quercetin, 3-Rhamnosyl-Glucosyl, Quercetin-3-Rutinoside, Rutin, Rutoside
Name | Rutin | ||
PubChem CID | 5280805 | ||
Molecular Weight | 610.5g/mol | ||
Synonyms |
3-Rhamnosyl-Glucosyl Quercetin, Quercetin 3 Rutinoside, Quercetin, 3-Rhamnosyl-Glucosyl, Quercetin-3-Rutinoside, Rutin, Rutoside |
||
Formula | C₂₇H₃₀O₁₆ | ||
SMILES | CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O | ||
InChI | 1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3/t8-,15+,17-,18+,20+,21-,22+,23+,26+,27-/m0/s1 | ||
InChIKey | IKGXIBQEEMLURG-NVPNHPEKSA-N | ||
CAS Number | 153-18-4 | ||
ChEMBL ID | CHEMBL226335 | ||
ChEBI ID | CHEBI:28527 | ||
Herb ID | HBIN042670 | ||
Drug Bank ID | DB01698 | ||
KEGG ID | C05625 | ||
Toxicity | Organism | Test Type | Route(Dose) |
rat | LD50 | intraperitoneal(165 mg/kg) | |
mouse | LD50 | intraperitoneal(254 mg/kg) | |
rat | LD50 | oral(322 mg/kg) | |
Structure |
Download
2D
MOL
3D
MOL
|
Chineses Pinyin | QiaoMai | ||
Use Part | Seed | ||
Habitat | China | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Caryophyllales
-->Family: Polygonaceae
-->Genus: Fagopyrum
-->Species: Fagopyrum esculentum
|
Pair Name | Rutin, Fluorouracil | |||
Partner Name | Fluorouracil | |||
Disease Info | [ICD-11: 2C82.0] | Prostate cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Up-regulation | Expression | TP53 | hsa7157 | |
In Vitro Model | PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 |
Result | Synergistic effects of 5-FU/rutin combination on PC3 cells line enhanced apoptosis, p53 gene expression, and down-regulation of Bcl-2 protein, compared to control separate application. 5-FU/rutin combination does seem an interesting therapeutic pathway to be further investigated. |
Pair Name | Rutin, Oxaliplatin | |||
Partner Name | Oxaliplatin | |||
Disease Info | [ICD-11: 2B72.Z] | Gastric cancer | Investigative | |
Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Up-regulation | Expression | BAX | hsa581 | |
Up-regulation | Phosphorylation | MAPK14 | hsa1432 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP7 | hsa840 | |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
In Vitro Model | SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 |
Result | P38 Signal Transduction Pathway Has More Cofactors on Apoptosis of SGC-7901 Gastric Cancer Cells Induced by Combination of Rutin and Oxaliplatin |
Pair Name | Rutin, Orlistat | |||
Partner Name | Orlistat | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | FAS | hsa355 |
Up-regulation | Expression | GSS | hsa2937 | |
In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 | |
Result | Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions |
No. | Title | Href |
---|---|---|
1 | P38 Signal Transduction Pathway Has More Cofactors on Apoptosis of SGC-7901 Gastric Cancer Cells Induced by Combination of Rutin and Oxaliplatin. Biomed Res Int. 2019 Nov 6;2019:6407210. doi: 10.1155/2019/6407210. | Click |
2 | Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions. Naunyn Schmiedebergs Arch Pharmacol. 2019 Feb;392(2):165-175. doi: 10.1007/s00210-018-1579-0. | Click |
3 | Synergetic Impact of Combined 5-Fluorouracil and Rutin on Apoptosis in PC3 Cancer Cells through the Modulation of P53 Gene Expression. Adv Pharm Bull. 2019 Aug;9(3):462-469. doi: 10.15171/apb.2019.055. | Click |